ORAI3 and prostate carcinoma: Dubois et al. [44] showed that enhanced ORAI3 expression favored heteromerization with ORAI1 to form a novel channel in in vitro models; the remodeled ORAI1–ORAI3 complex might serve as the oncogenic switch in prostate cancer (Fig. 1b).